Clinical Trial

A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to find out whether adding belumosudil to a usual approach for reducing the risk of graft-versus-host disease (GVHD) may be an effective GVHD prevention approach for people with blood cancer who have a stem cell transplant. The investigators will also look at the safety of the study approach.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-05-27; most recent amendment 2026-06-25.
Trial Details
NCT Number NCT07006506
Lead Sponsor Memorial Sloan Kettering Cancer Center
Conditions Graft Versus Host Disease, Graft Vs Host Disease, Hematologic Malignancy
Enrollment 46 participants
Start Date 2025-05-21
Primary Completion 2029-05-21 (estimated)
Study Completion 2029-05-21 (estimated)
Updated on ClinicalTrials.gov 2026-06-29